Once the diagnosis of autoimmune myasthenia gravis (MG) has been established, the clinician must develop an appropriate management plan. This review summarizes the available data regarding the natural course of the disease and the effect of the five commonly used therapies: cholinesterase inhibitors (CEIs), thymectomy, corticosteroids, nonsteroidal immunosuppressive drugs, and plasma exchange (PE). These data provide the basis for general guidelines of long-term management. All current therapies have limitations and drawbacks; therefore strategies for potential future therapy are addressed.
ASJC Scopus subject areas
- Clinical Neurology